# R1 CLINICAL-SAFETY REVIEW — pleuropulmonary_blastoma

VERDICT: APPROVE

goldens changed: no (intended: n/a — reference narrative, no engine/golden touched)

## 1. Safety
No unsafe, misleading, or harmful statement. No absolute/definitive claim that oversteps
decision-support. Key safety-positive features:
- Type I "resect even when imaging looks benign" is correct and safety-forward (occult malignant
  potential + progression risk to Type II/III is real; under-treating a presumed benign CPAM is the
  actual clinical hazard). Correctly hedged as standard, not a directive.
- Brain/bone surveillance for solid-type (Type II/III) disease matches PPB's known metastatic
  pattern — omitting it would be the harm; including it is protective.
- Radiotherapy framed as selective and balanced against long-term risk in a young child. Good.

## 2. Grounding
Consistent with standard pediatric-oncology / International PPB Registry / DICER1-syndrome
literature. No fabricated or outdated regimen: chemo is described only by drug class (alkylating +
anthracycline + vinca/actinomycin backbone), which maps correctly to the registry IVA/IVADo-type
approach without naming a protocol. DICER1-associated tumor spectrum listed is accurate (cystic
nephroma, Sertoli-Leydig, multinodular goitre/thyroid ca, ciliary body medulloepithelioma, nasal
chondromesenchymal hamartoma). Type I/Ir/II/III staging-by-type is correct.

Critically: NO claim is mis-attributed to DeVita. The draft transparently states DeVita's 12th ed.
section has no substantive PPB management content and inline-tags EVERY clinical claim as "general
oncology standard, not from DeVita's section on this disease." This is exactly the required handling
and is independently corroborated by the adversarial verdict (devita.txt line 67647 = bare WHO
classification table; line 67933 DICER1/TP53/CTNNB1 hit belongs to adult "pulmonary blastoma," a
different entity, and is correctly NOT cited here).

## 3. Dose-free
Confirmed. No mg, mg/m2, mg/kg, AUC, Gy/cGy, cycle/day numbers, or numbered schedules. Explicitly
defers doses/schedules to a structured protocol reference. Clean.

## 4. Scope
Appropriately hedged as decision-support: "considered," "selective role," "individualised,"
"case-by-case," "should be referred." No directive commands. Sources line honestly qualifies the
citation rather than overclaiming grounding; states NCCN not consulted.

## 5. Adversarial flags
.verdict.md = CLEAN (ready for R1). It raised NO still-present ungrounded/mis-sourced/scope-creep
claim. The only flag is a documented DeVita-grounding GAP (not a defect): DeVita genuinely lacks PPB
management content and the draft disclosed this instead of fabricating support. No blocking condition
under my rules is met (no DeVita-cited claim absent from DeVita).

## Advisory (non-blocking)
- "occult malignant cambium layer" — "cambium layer" is classically the RMS/sarcoma-botryoides term;
  in Type I PPB the malignant potential is a primitive small-cell/mesenchymal population beneath the
  cyst epithelium. Concept correct, term loosely borrowed. Consider "occult primitive malignant cell
  population in the cyst wall" for precision. Not a safety issue.
- Carry the file's own recommendation forward: flag for manual sourcing against a pediatric-oncology
  text / COG–International PPB Registry protocol before treating as fully grounded.

APPROVE: clinically safe, grounded with no DeVita mis-attribution, dose-free, appropriately scoped.
